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Abstract 
Neoplasm history increases morbidity and mortality after solid organ transplantation and has disqualified patients 
from transplantation. Studies are needed to identify factors to be considered when deciding on the suitability of a 
patient with previous tumor for heart transplantation. A retrospective epidemiological study was conducted in heart 
transplant (HT) recipients (Spanish Post–Heart Transplant Tumor Registry) comparing the epidemiological data, 
immu-nosuppressive treatments and incidence of post-HT tumors between patients with previous malignant 
noncardiac tumor and with no previous tumor (NPT). The impact of previous tumor (PT) on overall survival (OS) 
was also assessed. A total of 4561 patients, 77 PT and 4484 NPT, were evaluated. The NPT group had a higher 
proportion of men than the PT group (p < 0.001). The incidence of post-HT tumors was 1.8 times greater in the PT 
group (95% confidence interval [CI] 1.2–2.6; p < 0.001), mainly due to the increased risk in patients with a previous 
hematologic tumor (rate ratio 2.3, 95% CI 1.3–4.0, p < 0.004). OS during the 10-year posttransplant period was 
significantly lower in the PT than the NPT group (p = 0.048) but similar when the analysis was conducted after a first 
post-HT tumor was diagnosed. In conclusion, a history of PT increases the incidence of post-HT tumors and should 
be taken into account when considering a patient for HT. 
Abbreviations: ATG, antithymocyte globulin; AZA, azathioprine; CIC, chemotherapy-induced cardiomyopathy; CI, 
confidence interval; CsA, cyclosporine A; HR, hazard ratio; HT, heart transplant; MMF, mycophenolate mofetyl; 
MPS, mycophenolate sodium; mTOR, mammalian target of rapamycin; NPT, no previous tumor; OKT3, Orthoclone 
OKT3; OS, overall survival; PT, previous tumor; RR, rate ratio; SPHTTR, Spanish Post–Heart Transplant Tumor 
Registry; TAC, tacrolimus 
Introduction 
Neoplasm history classically has been considered a condition that increases posttransplant morbidity 
and mortality because of recurrence of the pretransplant malignancy or occurrence of a new one and has 
disqualified patients from transplantation. The frequent occurrence of neoplasm in these patients is 
probably favored by the effect of the immunosuppressive treatment used [1, 2] as well as the individual 
predisposition of the patient that contributed to the original neoplasm. 
Organ transplant recipients are at increased risk of malignancies, especially certain types, compared 
with the general population [3-5]. In the case of heart transplant (HT), the incidence of post-HT neoplasm 
is higher than among recipients of other organs and is a strong limitation of long-term survival [3, 6]. 
Previous neoplasms seem to increase the already high risk of post-HT tumors; however, successful cases 
of HT in patients with previous malignancies have been reported since the 1990s [7]. 
In liver transplantation for hepatoblastoma, several tumor-related variables have been identified that 
have an impact on recurrence of the tumor in the transplanted organ [8], and the success of liver 
transplantation for hepatocellular carcinoma has been shown to depend on careful patient selection on the 
basis of the Milan criteria (patients with a single tumor ≤5 cm or no more than three tumors, each no 
larger than 3 cm) [9-11]. The consideration of certain cancer-associated factors in patients with previous 
tumors have also been recommended for the indication of renal transplantation [12]. In a similar fashion, 
recommendations for the selection of HT candidates have been stated with regard to cancer [13]. The 
transplant recipient is assessed to rule out any current neoplasm, and when a history of neoplasm exists, 
transplantation is considered only once the cancer-free interval meets the length of time for the cancer to 
be considered cured, usually 5 years [13-15]. 
Further studies are needed to determine other putative factors that may influence the post-HT 
recurrence of a previous tumor and the occurrence of new tumors after HT in patients with pre-HT history 
of malignancy. A comparison of the aforementioned patients with HT patients who had no previous 
tumor (NPT) might help identify these factors as well as characterize the patients. To know more about 
these patients to make more precise informed decisions when indicating HT, a study in patients from the 
Spanish Post–Heart Transplant Tumor Registry (SPHTTR) was conducted to compare HT recipients who 
had a previous history of neoplasm with those who had no previous history. 
Materials and Methods 
A historical cohort study was conducted in HT recipients included in the SPHTTR from 1984 to 
December 31, 2010. The SPHTTR continually updates data on tumors for every patient undergoing HT at 
age ≥16 years in Spain since 1984, when HT was initiated in that country. The SPHTTR is a standardized 
database that includes 175 clinical variables with data on recipients, donors, surgery, immunosuppression 
and follow-up [16]. The use of a similar database by all Spanish transplant teams confers high reliability 
for the results [16]. This registry is one of the largest national heart transplant registries and contributes to 
other larger international registries, such as the International Registry for Heart and Lung Transplantation 
[17]. In addition, it probably has one of the largest samples of HT patients with previous tumors. 
The main objective of the study was to describe the profile of the HT recipients with a history of 
previous neoplasia and to compare their epidemiological data (age and sex), baseline and subsequent 
immunosuppression, and the incidence of post-HT tumors with the rest of the HT population in Spain 
with NPT. In addition, the possible impact of previous tumor (PT) history on overall survival (OS) 
compared with the OS of patients with NPT was evaluated. 
Patients included in the study should have survived >3 mo after transplantation. For the PT group, 
patients with previous nonmalignant tumors were excluded from the analysis, as were those with cardiac 
angiosarcoma because patients with this type of tumor are no longer transplanted due to the high 
recurrence rate [18]. In addition, retransplanted patients were excluded because retransplantation is a 
significant risk factor for cancer [19]. 
The types of pre-HT tumors were described for the PT group, and the types of post-HT tumors were 
described for both groups. Localization and histology were considered for the classification of tumor 
types: solid tumor (e.g. breast, prostate, colon, stomach, kidney, bladder, and lung carcinoma), melanoma, 
hematologic tumor (multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia), 
nonmelanocytic skin tumor (e.g. epidermoid and basocellular carcinoma) and Kaposi sarcoma. 
The research protocol was approved by the institutional review board of the University 12 de Octubre 
Hospital (Madrid, Spain; number 13/267), and the study was conducted according to Spanish regulations. 
The retrospective design of the study made it difficult to locate patients (some of them already dead), 
and because the patients were codified in the registry (maintaining their anonymity), informed consents 
were not required to conduct the study. Patients gave their consent to have their data included in the 
registry database. 
Statistical analysis 
Categorical variables were described by means of absolute and relative frequency tables, whereas 
continuous variables were described by central and dispersion measurements. The Pearson Chi-square test 
was used to compare the distribution of the categorical variables between the PT and NPT groups. 
The incidence rate of post-HT tumor and the mortality rate per 1000 person-years were assessed for 
each group as well as the ratios between rates (rate ratio [RR]). OS during the first 10 years after 
transplant was estimated by Kaplan–Meier curves for the PT and NPT groups, and the two curves were 
compared with the log-rank test. December 31, 2010, was considered the end of follow-up. All statistical 
calculations were performed using Stata version 10.1 for Windows (StataCorp, College Station, TX). 
  
Results 
At the time of the study, the SPHTTR contained records for 5672 patients who had undergone HT in 
Spain at age ≥16 years between 1984 and the end of 2010. Of these, 1025 died within 3 mo of HT, and 86 
met other exclusion criteria (Figure 1). Consequently, 4561 patients, 77 (1.7%) with PT (malignant 
noncardiac neoplasia) and 4484 (98.3%) with NPT, were included in this analysis. 
 
 
 
Figure 1. Patient disposition flow chart. NPT, no previous tumor; PT, previous tumor; SPHTTR, Spanish Post–Heart Transplant 
Tumor Registry. 
The sociodemographic and clinical characteristics of the patients are shown in Table 1. There were 
significantly more men in the NPT group than in the PT group (84% vs. 62%; p < 0.001), but age 
distribution was similar in both groups (p = 0.459). Every patient with a previous tumor had been 
considered cured by the multidisciplinary transplantation medical team, with a mean time since cancer 
diagnosis to the transplant of 8.3 years. In the PT group, 64% of previous tumors were solid tumors, 31% 
were hematologic and 5% were melanomas. Regarding tumor stage, 84.4% were localized tumors, and 
cancer spread in 12 patients (7 hematologic neoplasia and 5 solid tumors with local extension but no 
further dissemination). 
 
  
Table 1. Sociodemographic and clinical characteristics of the HT recipients included in the analyses 
 
PT patients (n = 77) NPT patients (n = 4484) p-value 
Men 48 (62.3) 3760 (83.8) <0.001 
Age (years) 
<45 17 (22.1) 998 (22.3) 
0.459 
45–54 19 (24.7) 1.339 (29.9) 
55–64 32 (41.6) 1.816 (40.5) 
≥65 9 (11.7) 331 (7.4) 
Time from neoplasia diagnosis to HT (years) 8.3 [2.2, 12.7] – – 
Indication for HT 
CIC 18 (23.4) – – 
Incidence of post-HT tumors 44.27 [19.89, 98.55] – – 
Rate of post-HT tumors 6 (33.3) – – 
Other cardiopathy 59 (76.6) – – 
Incidence of post-HT tumors 67.72 [45.39, 101.04] – – 
Rate of post-HT tumors 24 (40.7) – – 
Pre-HT tumor type 
Solid tumors 49 (63.6) – – 
Breast carcinoma 13 (16.9) 
  
Colon carcinoma 9 (11.7) 
  
Prostate carcinoma 6 (7.8) 
  
Kidney carcinoma 6 (7.8) 
  
Bladder carcinoma 5 (6.5) 
  
Stomach carcinoma 2 (2.6) 
  
Other 8 (10.4) 
  
Hematologic tumors 24 (31.2) – – 
Hodgkin lymphoma 11 (14.3) 
  
Leukemia 6 (7.8) 
  
Non-Hodgkin lymphoma 4 (5.2) 
  
Multiple myeloma 3 (4.0) 
  
Melanoma 4 (5.2) – – 
Stage 
Localized disease 65 (84.4) – – 
Extended disease 12 (15.6) – – 
Induction 
No 15 (19.5) 1263 (28.2) 
≤0.0001 OKT3/ATG/thymoglobulin/ 21 (27.3) 1973 (44.1) 
Basiliximab/daclizumab 41 (53.2) 1241 (27.7) 
    
 
Data expressed as n (%) for categorical variables and as mean [25th, 75th percentiles] for continuous variables. 
ATG, antithymocyte globulin; CIC, chemotherapy-induced cardiomyopathy; HT, heart transplant; OKT3, 
Orthoclone OKT3; NPT, no previous tumor; PT, previous tumor. 
  
Immunosuppressive treatment 
The most frequent immunosuppressive drugs used in both groups were prednisone (in almost every 
patient) and cyclosporine A (CsA; ≥74%) (Figure 2), which were administered mainly during the first 3 
mo after HT and decreased gradually thereafter. Azathioprine (AZA) also decreased with time but seemed 
to be used in a larger proportion of NPT than PT patients. Mycophenolate mofetyl (MMF) decreased with 
time only in the PT group; use stayed at similar proportions in the NPT group. Tacrolimus (TAC) stayed 
in similar levels up to 2 years and seemed to be used in a higher proportion of PT than NPT patients. 
Muromonab CD3 (Orthoclone OKT3 [OKT3]; Janssen Biotech, Horsham, PA), antithymocyte globulin 
(ATG), thymoglobulin and IL-2R blockers (basiliximab and daclizumab) were typically used only during 
the first 3 mo after HT because they are used mostly as induction therapy. A significantly (p ≤ 0.0001) 
larger proportion of PT patients received induction compared with NPT patients (80.5% vs. 71.8%, 
respectively) (Table 1). In contrast, sirolimus and everolimus were typically used after 3 mo, even more 
after 2 years, with everolimus used in higher proportions of PT than NPT patients. Globally, a higher 
percentage of PT than NPT patients seemed to use TAC, MMF, everolimus, basiliximab and daclizumab, 
whereas a higher percentage of NPT than PT patients seemed to use AZA, OKT3 and thymoglobulin 
(Figure 2). 
 
 
 
Figure 2. Immunosuppressive treatments. ATG, antithymocyte globulin; CsA, cyclosporine A; MMF, mycophenolate mofetil; 
MPS, mycophenolate sodium; NPT, no previous tumor; OKT3, Orthoclone OKT3; PT, previous tumor. 
  
Incidence of posttransplant tumors 
In the post-HT period, 1281 tumors developed in 914 patients (30 tumors in 25 PT patients and 1251 
tumors in 889 NPT patients). The different types of tumors developed are shown in Table 2. The 
incidence of post-HT tumors was greater in the PT group than in the NPT group (RR 1.8, 95% confidence 
interval [CI] 1.2–2.6, p < 0.001) because of an excess risk among patients with a pre-HT hematologic 
tumor (RR 2.3, 95% CI 1.3–4.0, p = 0.04) (Table 3). When excluding the four cases considered as 
relapsing malignancies (one hematologic neoplasia and three solid tumors), the incidence of post-HT 
tumors was still greater in the PT than the NPT group (RR 1.6, 95% CI 1.1–2.4, p = 0.016) (Table 3). 
Table 2. Post–heart transplant tumors 
 
PT group patients (n = 77) NPT group patients (n = 4484) 
Solid tumors 11 (14.3) 415 (9.2) 
Breast carcinoma 2 (2.6) 5 (0.1) 
Colon carcinoma 2 (2.6) 45 (1.0) 
Prostate carcinoma 1 (1.3) 73 (1.6) 
Bladder carcinoma 1 (1.3) 41 (0.9) 
Lung carcinoma 3 (3.9) 124 (2.8) 
Other 2 (2.6) 104 (2.3) 
Unknown 0 (0.0) 23 (0.5) 
Hematologic tumors 3 (3.9) 108 (2.4) 
Hodgkin lymphoma 1 (1.3) 4 (0.1) 
Leukemia 0 (0.0) 7 (0.1) 
Non-Hodgkin lymphoma 0 (0.0) 82 (1.8) 
Multiple myeloma 2 (2.6) 6 (0.1) 
Unknown 0 (0.0) 9 (0.2) 
Melanoma 2 (2.6) 13 (0.3) 
Nonmelanocytic skin tumors 11 (14.3) 668 (14.9) 
Epidermoid carcinoma 8 (10.4) 374 (8.3) 
Basocellular carcinoma 2 (2.6) 226 (5.0) 
Other 0 (0.0) 45 (1.0) 
Unknown 1 (1.3) 23 (0.5) 
Kaposi sarcoma 0 (0.0) 12 (0.3) 
Unknown 3 (3.9) 35 (0.8) 
   
 
Data expressed as number of tumors (%). 
NPT, no previous tumor; PT, previous tumor. 
  
Table 3. Incidence rates of post-HT tumors and mortality in the PT and NPT groups 
 At risk person-years Post-HT tumors Incidence ratea 95% CI RRb 95% CI p-valuee 
 
Post-HT tumors 
NPT 36 543.1 1251 34.2 32.4 36.2 1.0 – – – 
PT 490.5 30 61.2 42.8 87.5 1.8 1.2 2.6 0.001 
Solid tumor 316.2 14 44.3 26.2 74.8 1.3 0.8 2.2 0.337 
Hematologic tumor 154.3 12 77.8 44.2 136.9 2.3 1.3 4.0 0.004 
PT versus NPT 
adjustedc      
1.9f 1.3 2.7 <0.001 
PT versus NPT 
adjustedd      
1.8f 1.3 2.6 0.001 
Post-HT tumors excluding relapses 
NPT 36 532.7 1250 34.2 32.4 36.2 
    
PT 474.2 26 54.8 37.3 80.5 1.6 1.1 2.4 0.016 
Mortality 
NPT 36 532.7 1696 46.4 44.3 48.7 1.0 – – – 
PT 493.9 29 58.7 40.8 84.5 1.3 0.9 1.8 0.209 
Solid tumor 319.7 16 50.1 30.7 81.7 1.1 0.7 1.8 0.764 
Hematologic tumor 154.3 10 64.8 34.9 120.5 1.4 0.8 2.6 0.291 
          
 
CI, confidence interval; HT, heart transplant; NPT, no previous tumor; PT, previous tumor; RR, rate ratio. 
a  Incidence rate per 1000 person-years. 
b  RR with respect to the NPT group. 
c  NPT versus PT adjusted by induction. 
d  NPT versus PT adjusted by time period. 
e  The p-value is from the chi-square test; p-values in bold are significant. 
f  Adjusted RRs are calculated with the Mantel-Haenszel method. 
 
Chemotherapy-associated cardiomyopathy and posttransplant tumors 
Overall, 18 of the 77 patients with PT required HT because of chemotherapy-induced cardiomyopathy 
(CIC). No significant differences in the incidence rate or in the types of post-HT tumors were shown 
between those patients with CIC and those requiring HT due to other cardiopathies (RR 1.53, 95% CI 
0.62–3.74, p = 0.348) (Table 1). 
Induction therapy and posttransplant tumors 
Patients receiving induction had greater incidence of post-HT tumors than those not receiving 
induction (RR 1.98, 95% CI 1.71–2.28, p ≤ 0.0001) because of excess risk in patients receiving classic 
induction (OKT3, ATG and thymoglobulin; RR 2.20, 95% CI 1.91–2.55, p ≤ 0.0001) (Table 4). This 
finding was the same when looking exclusively at patients with NPT. In the PT group, it seemed there 
was no difference in the incidence of post-HT tumors whether or not patients received induction, but this 
is probably due to the small sample size. 
  
Table 4. Incidence rates of post-HT tumors in patients submitted or not to induction treatment 
 
At risk person-years Post-HT tumors Incidence ratea 95% CI RRb 95% CI p-valuec 
Post-HT tumors 
No induction 11 217.15 231 20.59 18.10 23.43 1.00 – – – 
Induction 25 816.40 1050 40.67 38.28 43.21 1.98 1.71 2.28 ≤0.0001 
OKT3/ATG/thymoglobulin 19 941.48 905 45.38 42.52 48.44 2.20 1.91 2.55 ≤0.0001 
Basiliximab/daclizumab 5835.65 145 24.85 21.11 29.24 1.21 0.98 1.49 0.076 
Post-HT tumors in NPT patients 
No induction 11 091.89 227 20.47 17.97 23.31 1.00 – – – 
Induction 25 451.21 1024 40.23 37.84 42.78 1.97 1.70 2.27 ≤0.0001 
OKT3/ATG/thymoglobulin 19 731.03 890 45.11 42.24 48.17 2.20 1.91 2.55 ≤0.0001 
Basiliximab/daclizumab 5680.91 134 23.59 19.91 27.94 1.15 0.93 1.43 0.192 
Post-HT tumors in PT patients 
No induction 125.26 4 31.93 11.99 85.08 1.00 – – – 
Induction 365.19 26 71.2 48.48 104.57 2.23 0.78 6.39 0.125 
OKT3/ATG/thymoglobulin 210.45 15 71.28 42.97 118.23 2.23 0.74 6.72 0.143 
Basiliximab/daclizumab 154.74 11 71.09 39.37 128.36 2.23 0.71 6.99 0.159 
          
 
ATG, antithymocyte globulin; CI, confidence interval; HT, heart transplant; OKT3, Orthoclone OKT3; RR, rate ratio. 
a  Incidence rate per 1000 person-years. 
b  RR with respect to no induction. 
c  The p-value is from the chi-square test. 
 
When the incidence rates of post-HT tumors were adjusted by induction, PT patients receiving 
induction showed an RR of 1.9 more risk of post-HT tumors than NPT patients receiving induction (95% 
CI 1.3–2.7, p < 0.01) (Table 3). 
Time period and posttransplant tumors 
The incidence rate of post-HT tumors was 32.77% (95% CI 29.09–36.90) when transplantation was 
performed between 1984 and 1992, 39.52% (95% CI 36.93–42.30) between 1993 and 2001, and 22.99% 
(95% CI 19.84–26.65) between during 2002 and 2010. 
When post-HT tumor incidence rates were adjusted by time period, PT patients had a risk of post-HT 
tumors that was 1.8 times greater than that of NPT patients (95% CI 1.3–2.6; p = 0.001) (Table 3). 
Posttransplant mortality and OS 
No significant differences were observed in post-HT mortality incidence rates or hazard ratios (HRs) 
between the groups (Tables 3 and 5). Women had significantly lower mortality risk than men, and 
mortality decreased significantly in more recent periods (Table 5). Mortality HRs were adjusted by sex 
and time period, but again, no significant differences were observed between the PT and NPT groups 
(Table 5). 
  
Table 5. Mortality by Cox regression analysis 
 
HR 95% CI p-value 
Pre-HT tumor 
No 1 
   
Yes 1.26 0.87 1.82 0.217 
Adjusted pre-HT tumora 
No 1 
   
Yes 1.41 0.98 2.04 0.068 
Sex 
Men 1 
   
Women 0.76 0.66 0.87 <0.001 
Time period 
1984–1992 1 
   
1993–2001 0.79 0.70 0.88 <0.001 
2002–2010 0.59 0.51 0.69 <0.001 
     
 
The p-values in bold are significant. 
CI, confidence interval; HR, hazard ratio; HT, heart transplant. 
a  Adjusted by sex and period year. 
OS during the 10-year posttransplant period was significantly greater in the NPT than the PT group (p 
= 0.048) (Figure 3A), showing the following survival data for NPT and PT groups, respectively: 93% and 
95% at 1 year, 79% and 74% at 5 years, and 65% and 51% at 10 years. When the survival analysis was 
performed after the diagnosis of the first post-HT tumor (Figure 3B), no significant survival differences 
were observed between the groups. 
  
 
 
 
Figure 3. Kaplan-Meier survival curves for patients with PT and NPT. (A) Starting right after transplantation. (B) Starting at the 
time of first post–heart transplant diagnosed tumor. NPT, no previous tumor; PT, previous tumor. 
  
Table 6 shows the causes of mortality in both groups. Cancer-related death was 21.3% and 32.2% in 
the NPT and PT groups, respectively. 
Table 6. Cause of death in the PT and NPT groups 
 
PT n (%) NPT n (%) 
Deaths, total 28 (36.4) 1560 (34.8) 
Cardiovascular 3 (10.7) 356 (22.8) 
Cerebrovascular 4 (14.3) 52 (3.3) 
Graft failure 7 (25.0) 318 (20.4) 
Acute rejection 4 (14.3) 112 (7.2) 
Chronic rejection 3 (10.7) 139 (8.9) 
Other 0 (0.0) 67 (4.3) 
Hemorrhage 0 (0.0) 14 (0.9) 
Infection 2 (7.1) 231 (14.8) 
Bacterial 0 (0.0) 188 (12.1) 
Fungal 1 (3.6) 20 (1.3) 
Viral 1 (3.6) 14 (0.9) 
Other 0 (0.0) 9 (0.6) 
Malignancy 9 (32.1) 333 (21.3) 
Posttransplant lymphoproliferative disease 0 (0.0) 39 (2.5) 
Skin 0 (0.0) 9 (0.6) 
Other 9 (32.1) 285 (18.3) 
Multiple organ failure 0 (0.0) 73 (4.7) 
Pulmonary 1 (3.6) 44 (2.8) 
Other 2 (7.1) 139 (8.9) 
   
 
NPT, no previous tumor; PT, previous tumor. 
 
Discussion 
The current study shows that the tumor incidence rate in post-HT patients with PT history was almost 
double that of post-HT patients with NPT history (RR 1.8, p ≤ 0.001), in agreement with previous studies 
showing higher incidence of de novo tumors in posttransplant patients with PT history [20, 21]. In the 
study by Higgins et al conducted in 6211 U.S. HT recipients, of whom 283 had pretransplant 
malignancies, a multivariate analysis showed that previous history of cancer had a relative risk of 1.6 (p = 
0.02) for posttransplant tumors, although older age and earlier date of transplant were the two most 
significant risk factors. In agreement with these data, our study showed that post-HT tumor incidence 
rates were higher at earlier dates of transplant compared with more recent dates. 
It is important to note that in the current study, the tumor incidence rates in the group with previous 
solid tumors and in the NPT group were similar, and it was only that of the group with previous 
hematologic tumors that was significantly larger compared with the rate in the NPT group (RR 2.3, p ≤ 
0.004). Some tumors, including hematologic tumors, are prone to genomic instability, namely, an 
increased tendency of tumor cells to acquire new mutations with each cell division [22, 23]. In addition, 
leukemia cells have been shown to release fragmented DNA derived from their genome, which may enter 
the nuclei of other cells and induce double-strand breaks or integrate into the chromosomal DNA, 
promoting genome instability of these cells [24]. All of these aspects might help explain the greater 
incidence of post-HT tumors in patients with such a history of cancer. In agreement with this theory, 
Bratsttrom et al showed that the type of previous malignancy had a great impact on cancer recurrence and 
mortality, with hematologic cancer showing the greater overall and cancer-specific mortality among the 
different pretransplant cancer types [25]. 
The incidence rates of tumors in the NPT group (34.2 per 1000 person-years) and the PT group (61.2 
per 1000 person-years) were much higher than the rate estimated by Globocan 2008 for the overall 
Spanish population (4.4 per 1000 person-years for all cancers, excluding nonmelanoma skin cancer) [26], 
as expected for patients submitted to transplantation. Skin cancer, especially nonmelanoma skin cancer, 
represented a major proportion of the post-HT tumors, in agreement with previous data, showing this 
cancer type as the most common to develop de novo in recipients of organ transplant overall and in 
recipients of HT specifically [5, 27-29]. Eleven de novo nonmelanocytic skin cancers arose in 77 patients 
with previous cancer history (14.3%), and the frequency of skin cancer in patients without a cancer 
history was similar at 14.9% (668 de novo tumors in 4484 patients). Noncutaneous solid tumors arose in 
14.3% of patients with PT (three considered relapsing malignancies [two colon carcinomas, one bladder 
carcinoma]) and 9.3% of patients with NPT. Lung cancer was the most common one, in agreement with 
data from a study assessing post-HT lung cancer incidence [30] and other studies showing lung cancer as 
one of the most frequently developing solid tumors in HT recipients [19, 21, 31, 32]. Hematologic tumors 
developed in 3.9% (three of 77) of PT patients (one tumor was multiple myeloma, considered a relapsing 
malignancy) and 2.4% (108 of 4484) of NPT patients. One-third of the PT patients had a history of 
hematologic tumors, and such tumors are likely to recur [25]. Still, the frequency of recurrence was low 
(5.2% or 4% in 77 patients), as observed by Higgins et al [21]. The proportion of post-HT multiple 
myeloma was higher in the PT than the NPT group (2.6% vs. 0.1%, respectively), although the latter 
group had a higher proportion of men, and multiple myeloma is known to be more common in men than 
in women [33]. 
Immunosuppressive treatments affect the cancer risk of transplanted patients [29]. Drugs used for 
induction, other than IL-2R blockers, have been shown to increase the risk of neoplasia [34-36]. The 
mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are known to show 
anticancer effects in HT recipients and other solid organ recipients [37-39]. The use of induction therapy 
has increased in recent years, and the drugs used have changed from mainly OKT3 and ATG to 
daclizumab and, especially, basiliximab [16]. In addition, mTOR inhibitors have been available only 
recently [37-39]. The immunosuppressive regimen used in HT in Spain has evolved from OKT3 
induction and maintenance with CsA, AZA and steroids to basiliximab induction and maintenance with 
CsA/TAC, MMF and steroids [40]. According to the changes in immunosuppressive drugs used, patients 
transplanted more recently showed significantly lower posttransplant tumor rates. In addition, patients 
receiving induction therapy showed increased post-HT tumor rates over those with no induction, due to 
the increased rate in the group induced by classic induction drugs (OKT3, ATG, and thymoglobulin). No 
such effect was observed when induction was performed with the IL-2R blockers basiliximab or 
daclizumab. Because most patients with previous tumors were transplanted recently (this type of patient 
has been considered for HT only recently), immunosuppressive treatments differed between them and 
patients with NPT. When incidence rates were adjusted by time period or by induction, the PT group still 
showed a post-HT tumor rate almost twofold greater than the NPT group. The use of antineoplastic 
treatments in PT patients prior to HT might also influence the incidence of post-HT treatment; however, 
when patients who were transplanted due to chemotherapy-induced cardiomyopathy were compared with 
those transplanted for other indications, no significant differences in post-HT tumor incidence rates were 
observed. 
OS was significantly better in the NPT than the PT group during the first 10-year posttransplant 
period, a difference that started being noticeable only by the fifth or sixth year. The similar survival data 
between the groups during the first 4–5 years after transplant seem to agree with a previous study 
conducted in Spain that showed similar actuarial survival at 1, 3, and 5 years in the PT and NPT groups 
[41]. In the study by Higgins et al [21], the percentage of patients free from malignancy, which was 
significantly lower in the PT group compared with the NPT group in the 15-year posttransplant period, 
did not start to show noticeable differences between groups until the fifth or sixth year. Consequently, the 
appearance of a survival difference between our two groups of patients only 5 years after transplant might 
reflect the different timing of occurrence of the first posttransplant tumors, which seem to occur earlier in 
the PT than the NPT group. In fact, when OS was estimated after the first tumors were diagnosed, no 
differences in survival were observed between the PT and NPT groups, further suggesting that the 
differences observed in survival from the fifth to the 10th year after transplant reflect an earlier 
appearance of tumors in the patients with a history of cancer. 
The mortality HR or instantaneous risk of dying was not significantly different between the PT and 
NPT groups (adjusted for sex and time period, HR 1.41 [95% CI 0.98-2.04, p = 0.068, Table 5). The 
study by Bratsttrom et al [25] conducted in a Swedish population-based cohort of 10 448 solid organ 
recipients, of whom 416 (4%) had a prior malignancy, showed an 80% increase in overall mortality 
(adjusted for sex, age and time period, HR 1.8 [95% CI 1.3–2.5]) among nonkidney recipients (including 
HT recipients) with cancer history, compared with those without such history, driven by cancer-specific 
death. Bratsttrom et al showed that the type of previous malignancy and the waiting time between cancer 
remission and transplantation had a great impact on relapses and mortality. Every PT patient in our study 
had been considered cured at the time of transplantation, with a mean interval of 8.3 years from diagnosis 
to transplant, and in fact, relapses were very uncommon. When HT started to be performed in patients 
with a history of tumors, the average cancer-free interval before transplantation was almost 10 years [42]; 
however, the current arbitrary threshold value for considering cancer cured is 5 years, although it depends 
on the cancer type [13, 43]. In the study by Bratsttrom et al, 45% of patients had a waiting time ≤5 years, 
and those patients, as well as those with a waiting time >10 years (29%), had significantly higher cancer-
related mortality than patients with a waiting time of 5–10 years [25]. This high percentage of patients 
with <5 years of waiting time might explain the increased mortality observed in the PT patients from the 
study by Bratsttrom et al; this did not show in our PT patients. 
A limitation of the current study might be the different sizes of the PT and NPT groups; however, the 
analyses were initially performed simply, with no adjustments, minimizing the possible problems that this 
difference might represent. Another limitation of the study is that although both groups were 
homogeneous in age, they differed in proportions of men and women, time period of transplantation and 
use of induction; however, the analyses were adjusted by sex, time period and induction, and results 
similar to the initial analyses were obtained. 
In conclusion, after adjusting the analyses by different variables, HT patients with previous malignant 
noncardiac tumors, specifically those with previous hematologic tumors, showed higher post-HT tumor 
incidence than those with NPT and worse OS over a 10-year period, most likely due to earlier occurrence 
of posttransplant tumors in patients with PT. Consequently, patients with a history of previous noncardiac 
tumor should be carefully considered for HT. In addition, when transplantation is carried out in such 
patients, they should be followed more carefully, with increasing surveillance for arising tumors during at 
least the first 5 years after transplant. 
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